SG11202105907QA - Compositions for drg-specific reduction of transgene expression - Google Patents
Compositions for drg-specific reduction of transgene expressionInfo
- Publication number
- SG11202105907QA SG11202105907QA SG11202105907QA SG11202105907QA SG11202105907QA SG 11202105907Q A SG11202105907Q A SG 11202105907QA SG 11202105907Q A SG11202105907Q A SG 11202105907QA SG 11202105907Q A SG11202105907Q A SG 11202105907QA SG 11202105907Q A SG11202105907Q A SG 11202105907QA
- Authority
- SG
- Singapore
- Prior art keywords
- drg
- compositions
- transgene expression
- specific reduction
- reduction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783956P | 2018-12-21 | 2018-12-21 | |
| US201962924970P | 2019-10-23 | 2019-10-23 | |
| US201962934915P | 2019-11-13 | 2019-11-13 | |
| PCT/US2019/067872 WO2020132455A1 (en) | 2018-12-21 | 2019-12-20 | Compositions for drg-specific reduction of transgene expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105907QA true SG11202105907QA (en) | 2021-07-29 |
Family
ID=71100588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105907QA SG11202105907QA (en) | 2018-12-21 | 2019-12-20 | Compositions for drg-specific reduction of transgene expression |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210077553A1 (en) |
| EP (1) | EP3908326A4 (en) |
| JP (1) | JP7660062B2 (en) |
| KR (1) | KR20210107037A (en) |
| CN (1) | CN113646005A (en) |
| AU (1) | AU2019401314A1 (en) |
| BR (1) | BR112021011143A2 (en) |
| CA (1) | CA3123600A1 (en) |
| CL (1) | CL2021001624A1 (en) |
| CO (1) | CO2021008538A2 (en) |
| IL (1) | IL284185B2 (en) |
| JO (1) | JOP20210160A1 (en) |
| MX (1) | MX2021007600A (en) |
| PE (1) | PE20211581A1 (en) |
| PH (1) | PH12021551341A1 (en) |
| SG (1) | SG11202105907QA (en) |
| WO (1) | WO2020132455A1 (en) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020270421A1 (en) | 2019-05-03 | 2021-11-18 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of metachromatic leukodystrophy |
| MX2022012752A (en) | 2020-04-15 | 2023-01-16 | Voyager Therapeutics Inc | Tau binding compounds. |
| WO2021231579A1 (en) * | 2020-05-12 | 2021-11-18 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| EP4149955A1 (en) | 2020-05-13 | 2023-03-22 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
| WO2021247995A2 (en) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
| JP2023531451A (en) | 2020-06-17 | 2023-07-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Compositions and methods for treatment of gene therapy patients |
| US20230270884A1 (en) | 2020-07-13 | 2023-08-31 | The Trustees Of The University Of Pennsylvania | Compositions useful for treatment of charcot-marie-tooth disease |
| MX2023000815A (en) | 2020-07-27 | 2023-04-11 | Voyager Therapeutics Inc | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency. |
| WO2022026410A2 (en) | 2020-07-27 | 2022-02-03 | Voyager Therapeutics, Inc | Compositions and methods for the treatment of niemann-pick type c1 disease |
| EP4229186A1 (en) | 2020-10-18 | 2023-08-23 | The Trustees of The University of Pennsylvania | Improved adeno-associated virus (aav) vector and uses therefor |
| WO2022094078A1 (en) | 2020-10-28 | 2022-05-05 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of rett syndrome |
| MX2023006445A (en) | 2020-12-01 | 2023-08-10 | Univ Pennsylvania | Compositions and uses thereof for treatment of angelman syndrome. |
| WO2022187548A1 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| US20240175050A1 (en) * | 2021-03-19 | 2024-05-30 | Mayo Foundation For Medical Education And Research | Methods and materials for treating propionic acidemia |
| WO2023113806A1 (en) | 2021-12-16 | 2023-06-22 | Affinia Therapeutics, Inc. | Recombinant aav for treatment of neural disease |
| EP4323531A1 (en) | 2021-04-12 | 2024-02-21 | Affinia Therapeutics Inc. | Recombinant aav for treatment of neural disease |
| WO2022226263A1 (en) | 2021-04-23 | 2022-10-27 | The Trustees Of The University Of Pennsylvania | Novel compositions with brain-specific targeting motifs and compositions containing same |
| WO2022232267A1 (en) | 2021-04-27 | 2022-11-03 | The Trustees Of The University Of Pennsylvania | Porcine-derived adeno-associated virus capsids and uses thereof |
| WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| EP4409010A1 (en) | 2021-10-02 | 2024-08-07 | The Trustees of The University of Pennsylvania | Novel aav capsids and compositions containing same |
| US20240425882A1 (en) * | 2021-10-18 | 2024-12-26 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of cdkl5 deficiency disorder (cdd) |
| WO2023087019A2 (en) * | 2021-11-15 | 2023-05-19 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| EP4433169A1 (en) | 2021-11-17 | 2024-09-25 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| US20250049955A1 (en) | 2021-11-17 | 2025-02-13 | Voyager Therapeutics, Inc. | Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2023133574A1 (en) | 2022-01-10 | 2023-07-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods useful for treatment of c9orf72-mediated disorders |
| EP4469585A2 (en) | 2022-01-25 | 2024-12-04 | Voyager Therapeutics, Inc. | Baculovirus expression system |
| TW202346599A (en) | 2022-02-08 | 2023-12-01 | 美商航海家醫療公司 | Aav capsid variants and uses thereof |
| CN119317645A (en) | 2022-04-06 | 2025-01-14 | 宾夕法尼亚州大学信托人 | Compositions and methods for treating HER2-positive metastatic breast cancer and other cancers |
| WO2023196892A1 (en) | 2022-04-06 | 2023-10-12 | The Trustees Of The University Of Pennsylvania | Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors |
| EP4522757A2 (en) | 2022-05-13 | 2025-03-19 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2023235791A1 (en) | 2022-06-02 | 2023-12-07 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| EP4543473A1 (en) | 2022-06-22 | 2025-04-30 | Voyager Therapeutics, Inc. | Tau binding compounds |
| AR129733A1 (en) | 2022-06-28 | 2024-09-25 | Voyager Therapeutics Inc | AAV CAPSID VARIANTS AND THEIR USES |
| WO2024011112A1 (en) | 2022-07-06 | 2024-01-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| WO2024008950A1 (en) * | 2022-07-08 | 2024-01-11 | Ospedale San Raffaele S.R.L. | Transgene cassettes |
| EP4565597A2 (en) | 2022-08-03 | 2025-06-11 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
| IL319121A (en) | 2022-09-15 | 2025-04-01 | Voyager Therapeutics Inc | Tau binding compounds |
| WO2024073310A2 (en) * | 2022-09-26 | 2024-04-04 | Encoded Therapeutics, Inc. | Elements for de-targeting gene expression in dorsal root ganglion and/or liver |
| TW202440939A (en) | 2022-12-17 | 2024-10-16 | 賓州大學委員會 | Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same |
| WO2024130070A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof |
| WO2024145474A2 (en) | 2022-12-29 | 2024-07-04 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
| WO2024163012A1 (en) | 2023-02-02 | 2024-08-08 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2024226761A2 (en) | 2023-04-26 | 2024-10-31 | Voyager Therapeutics, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
| WO2024228943A1 (en) | 2023-05-02 | 2024-11-07 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
| WO2024229161A1 (en) | 2023-05-03 | 2024-11-07 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency |
| WO2024229389A1 (en) | 2023-05-03 | 2024-11-07 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| TW202444917A (en) | 2023-05-04 | 2024-11-16 | 美商航海家醫療公司 | Aav capsid variants and uses thereof |
| WO2024235159A1 (en) * | 2023-05-12 | 2024-11-21 | 上海金珂博生物技术有限公司 | Viral vector carrying smn gene expression cassette and use thereof |
| WO2025007046A1 (en) | 2023-06-29 | 2025-01-02 | The Trustees Of The University Of Pennsylvania | Mutant aav with central nervous system targeting motifs and compositions containing same |
| WO2025035143A1 (en) | 2023-08-10 | 2025-02-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of spinal muscular atrophy |
| WO2025038805A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency |
| WO2025106661A1 (en) | 2023-11-14 | 2025-05-22 | The Trustees Of The University Of Pennsylvania | Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof |
| WO2025122530A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025122644A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
| WO2025129157A1 (en) | 2023-12-15 | 2025-06-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treatment of canavan disease |
| WO2025147436A1 (en) | 2024-01-03 | 2025-07-10 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1838870A2 (en) * | 2004-12-29 | 2007-10-03 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs |
| DK2002003T3 (en) * | 2005-05-27 | 2016-03-21 | Ospedale San Raffaele Srl | Gene vector comprising miRNA |
| US20100286044A1 (en) * | 2005-12-29 | 2010-11-11 | Exiqon A/S | Detection of tissue origin of cancer |
| EP2215228A4 (en) * | 2007-11-23 | 2012-01-11 | Panagene Inc | Microrna antisense pnas, compositions comprising the same, and methods for using and evaluating the same |
| US9217155B2 (en) * | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| EP3514232A1 (en) * | 2010-04-23 | 2019-07-24 | University of Massachusetts | Cns targeting aav vectors and methods of use thereof |
| FR3004463A1 (en) | 2013-04-11 | 2014-10-17 | Genethon | EXPRESSION SYSTEM FOR SELECTIVE GENE THERAPY |
| CA3012195A1 (en) * | 2016-02-03 | 2017-08-10 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type i |
| JOP20190200A1 (en) * | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | Compositions useful in treatment of spinal muscular atrophy |
-
2019
- 2019-12-20 SG SG11202105907QA patent/SG11202105907QA/en unknown
- 2019-12-20 BR BR112021011143A patent/BR112021011143A2/en unknown
- 2019-12-20 AU AU2019401314A patent/AU2019401314A1/en active Pending
- 2019-12-20 PE PE2021000908A patent/PE20211581A1/en unknown
- 2019-12-20 JO JOP/2021/0160A patent/JOP20210160A1/en unknown
- 2019-12-20 JP JP2021535718A patent/JP7660062B2/en active Active
- 2019-12-20 MX MX2021007600A patent/MX2021007600A/en unknown
- 2019-12-20 EP EP19897715.9A patent/EP3908326A4/en active Pending
- 2019-12-20 CA CA3123600A patent/CA3123600A1/en active Pending
- 2019-12-20 KR KR1020217021804A patent/KR20210107037A/en active Pending
- 2019-12-20 IL IL284185A patent/IL284185B2/en unknown
- 2019-12-20 WO PCT/US2019/067872 patent/WO2020132455A1/en active Application Filing
- 2019-12-20 CN CN201980092720.6A patent/CN113646005A/en active Pending
-
2020
- 2020-11-13 US US17/097,997 patent/US20210077553A1/en active Pending
-
2021
- 2021-06-07 PH PH12021551341A patent/PH12021551341A1/en unknown
- 2021-06-17 CL CL2021001624A patent/CL2021001624A1/en unknown
- 2021-06-29 CO CONC2021/0008538A patent/CO2021008538A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022517174A (en) | 2022-03-07 |
| CO2021008538A2 (en) | 2021-07-19 |
| IL284185B2 (en) | 2025-04-01 |
| US20210077553A1 (en) | 2021-03-18 |
| WO2020132455A1 (en) | 2020-06-25 |
| JOP20210160A1 (en) | 2023-01-30 |
| IL284185A (en) | 2021-08-31 |
| PE20211581A1 (en) | 2021-08-17 |
| CA3123600A1 (en) | 2020-06-25 |
| CL2021001624A1 (en) | 2021-11-26 |
| AU2019401314A1 (en) | 2021-06-24 |
| EP3908326A4 (en) | 2022-10-26 |
| JP7660062B2 (en) | 2025-04-10 |
| CN113646005A (en) | 2021-11-12 |
| IL284185B1 (en) | 2024-12-01 |
| BR112021011143A2 (en) | 2022-01-25 |
| EP3908326A1 (en) | 2021-11-17 |
| PH12021551341A1 (en) | 2021-12-13 |
| MX2021007600A (en) | 2021-08-11 |
| KR20210107037A (en) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202105907QA (en) | Compositions for drg-specific reduction of transgene expression | |
| GB201811312D0 (en) | Compositions | |
| GB2586745B (en) | Compositions | |
| GB201916960D0 (en) | Compositions | |
| DK3924442T3 (en) | Compositions | |
| SG11202104306XA (en) | Compositions | |
| SG11202009259VA (en) | Compositions | |
| IL287262A (en) | Methods and compositions for transgene expression | |
| IL289557A (en) | Sustained release compositions of endoxifen | |
| IL289125A (en) | Compositions | |
| GB201908396D0 (en) | Compositions | |
| EP4048785A4 (en) | COMPOSITIONS FOR DRG-SPECIFIC REDUCTION OF TRANSGENE EXPRESSION | |
| GB201803923D0 (en) | Compositions | |
| GB201913701D0 (en) | Composition of matter | |
| IL290324A (en) | Compositions of trofinetide | |
| PL3746114T3 (en) | Compositions for use to treat cataract | |
| GB201919180D0 (en) | New composition of matter | |
| KR102388028B9 (en) | Composition for delivering of polypptide | |
| GB201919234D0 (en) | Compositions | |
| HK40064210A (en) | Compositions for drg-specific reduction of transgene expression | |
| GB2570649B (en) | Compositions | |
| GB201805676D0 (en) | Compositions | |
| HK40078511A (en) | Compositions for drg-specific reduction of transgene expression | |
| IL263336B (en) | Compositions for treatment of symphysiolysis | |
| ZA202005658B (en) | Compositions |